Telma 40 mg Tablet

Telma 40 Mg Tablet contains active ingredients Telmisartan (40mg). It is prescribed to treat and manage hypertension (high blood pressure), heart failure, and prevention of heart attack.

Its composition like Telmisartan, is an angiotensin II receptor blocker that relaxes blood vessels & lowers blood pressure. This medicine also reduces the chances of any future heart attack and stroke.

It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.​

• Treatment of Hypertension (high blood pressure)
• Heart Failure
• Prevention of heart attack and stroke

Some of the medications caused side effects just like that Telma 40 Mg tablet may also lead to certain side effects in some patients. Discuss with the doctor if any of these symptoms persist or worsen:

• Back pain
• Sinus inflammation
• Skin ulcer
• Intermittent claudication
• Diarrhea

• Take Telma 40 Mg tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.​
  

• Telma 40 Mg Tablet contains active ingredients Telmisartan (40mg). Telmisartan, is an angiotensin II receptor blocker that relaxes blood vessels by inhibiting the action of a chemical that make blood vessels tighter.
• This medicine also lowers the blood pressure, allowing the blood to flow more smoothly to different organs and the heart to pump more efficiently to treat hypertension and chronic heart failure.​
  

• Deppe, S., Böger, R. H., Weiss, J., & Benndorf, R. A. (2010). Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert opinion on drug metabolism & toxicology, 6(7), 863-871. https://pubmed.ncbi.nlm.nih.gov/20509777/
• Mann, J. F., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., ... & TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. (2009). Effect of telmisartan on renal outcomes: a randomized trial. Annals of internal medicine, 151(1), 1-10. https://pubmed.ncbi.nlm.nih.gov/19451556/
• Yusuf, S., Diener, H. C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., ... & Yoon, B. W. (2008). Telmisartan to prevent recurrent stroke and cardiovascular events. New England Journal of Medicine, 359(12), 1225-1237. https://pubmed.ncbi.nlm.nih.gov/18753639/
• Battershill, A. J., & Scott, L. J. (2006). Telmisartan: a review of its use in the management of hypertension. Drugs, 66(1), 51-83. https://pubmed.ncbi.nlm.nih.gov/16398568/
• Frampton, J. E. (2011). Telmisartan: a review of its use in cardiovascular disease prevention. Drugs, 71(6), 651-677.